Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19

Advances Toward COVID-19 Therapies Special Issue

(2022) Nouri Neamati   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

(2022) E Wesley Ely et al.   Lancet Respiratory Medicine

Nirmatrelvir Plus Ritonavir: First Approval

(2022) Yvette N. Lamb   DRUGS

JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis

(2021) Chong-xiang Chen et al.   LEUKEMIA

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

(2021) Ronal Yosua Limen et al.   Expert Review of Anti-Infective Therapy

Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy

(2021) Thanigaimalai Pillaiyar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis

(2021) Caifang Zheng et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns

(2021) Owen Dyer   BMJ-British Medical Journal

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

(2020) Justin Stebbing et al.   EMBO Molecular Medicine

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

(2020) Yang Cao et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Immunomodulation in COVID-19

(2020) Nicholas E Ingraham et al.   Lancet Respiratory Medicine

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

(2020) Wei Luo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The COVID-19 Cytokine Storm; What We Know So Far

(2020) Dina Ragab et al.   Frontiers in Immunology

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

(2020) Enrico Capochiani et al.   Frontiers in Medicine

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

(2020) Hassan Yousefi et al.   BIOCHEMICAL PHARMACOLOGY

Drug repurposing approach to fight COVID-19

(2020) Thakur Uttam Singh et al.   Pharmacological Reports

FDA Approval of Remdesivir — A Step in the Right Direction

(2020) Daniel Rubin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases

(2019) Kathryn M. Kingsmore et al.   Nature Reviews Rheumatology

FDA approves Eli Lilly's baricitinib

(2018) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Drug repurposing: progress, challenges and recommendations

(2018) Sudeep Pushpakom et al.   NATURE REVIEWS DRUG DISCOVERY

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

(2017) Elena Bekerman et al.   JOURNAL OF CLINICAL INVESTIGATION

AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets

(2015) Gregory Neveu et al.   JOURNAL OF VIROLOGY

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

(2012) J. Mascarenhas et al.   CLINICAL CANCER RESEARCH

Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly

(2012) Gregory Neveu et al.   PLoS Pathogens

ADP-Glo: A Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases

(2010) Hicham Zegzouti et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD